Results 11 to 20 of about 1,721,954 (363)

Optimized Treatment Schedules for Chronic Myeloid Leukemia [PDF]

open access: yes, 2016
Over the past decade, several targeted therapies (e.g. imatinib, dasatinib, nilotinib) have been developed to treat Chronic Myeloid Leukemia (CML). Despite an initial response to therapy, drug resistance remains a problem for some CML patients.
Dingli, David   +4 more
core   +4 more sources

Pyroptosis-Related Subtypes Predict the Response of Clear Cell Renal Cell Carcinoma to Targeted Therapy

open access: yesFrontiers in Bioscience-Landmark, 2023
Background: Pyroptosis plays a crucial role in anti-tumor immunity and in formation of the immune microenvironment. However, whether pyroptosis is involved in the progression of clear cell renal cell carcinoma (ccRCC) is still unclear.
Jinpeng Ma   +12 more
doaj   +1 more source

Enhancing anti-tumour innate immunity by targeting the DNA damage response and pattern recognition receptors in combination with radiotherapy

open access: yesFrontiers in Oncology, 2022
Radiotherapy is one of the most effective and frequently used treatments for a wide range of cancers. In addition to its direct anti-cancer cytotoxic effects, ionising radiation can augment the anti-tumour immune response by triggering pro-inflammatory ...
Charleen M. L. Chan Wah Hak   +5 more
doaj   +1 more source

Mathematical Modeling Insights into Improving CAR T cell Therapy for Solid Tumors: Antigen Heterogeneity and Bystander Effects [PDF]

open access: yesnpj Systems Biology and Applications, 10(1), 105 (2024), 2023
As an adoptive cellular therapy, Chimeric Antigen Receptor T-cell (CAR T-cell) therapy has shown remarkable success in hematological malignancies, but only limited efficacy against solid tumors. Compared with blood cancers, solid tumors present a unique set of challenges that ultimately neutralize the function of CAR T-cells.
arxiv   +1 more source

Ursodeoxycholic acid suppresses the malignant progression of colorectal cancer through TGR5-YAP axis

open access: yesCell Death Discovery, 2021
The Hippo/YAP pathway plays an important role in the development of cancers. Previous studies have reported that bile acids can activate YAP (Yes Associated Protein) to promote tumorigenesis and tumor progression.
Huan Zhang   +4 more
doaj   +1 more source

Simultaneously targeting SOAT1 and CPT1A ameliorates hepatocellular carcinoma by disrupting lipid homeostasis

open access: yesCell Death Discovery, 2021
Lipid homeostasis plays a fundamental role in the development of hepatocellular carcinoma (HCC). However, the mechanisms that regulate lipid homeostasis to avoid lipotoxicity in HCC remain elusive.
Meiling Ren   +4 more
doaj   +1 more source

Cholesterol activates the Wnt/PCP-YAP signaling in SOAT1-targeted treatment of colon cancer

open access: yesCell Death Discovery, 2021
Intracellular free cholesterol can be converted to cholesteryl ester and stored as lipid droplets through SOAT1-mediated esterification. Compelling evidence implicate targeting SOAT1 as a promising therapeutic strategy for cancer management.
Huanji Xu   +4 more
doaj   +1 more source

Targeting SERT promotes tryptophan metabolism: mechanisms and implications in colon cancer treatment

open access: yesJournal of Experimental & Clinical Cancer Research, 2021
Background Serotonin signaling has been associated with tumorigenesis and tumor progression. Targeting the serotonin transporter to block serotonin cellular uptake confers antineoplastic effects in various tumors, including colon cancer.
Di Ye   +5 more
doaj   +1 more source

Development of a quantitative methylation-specific droplet digital PCR assay for detecting Dickkopf-related protein 3

open access: yesBMC Research Notes, 2022
Objective The detection and monitoring of DNA methylation status in circulating tumor cell DNA (ctDNA) provides critical insights into cancer diagnosis and progression.
Kenji Araki, Ai Kurosawa, Hiromi Kumon
doaj   +1 more source

OX40 and 4-1BB delineate distinct immune profiles in sarcoma

open access: yesOncoImmunology, 2022
Systemic relapse after radiotherapy and surgery is the major cause of disease-related mortality in sarcoma patients. Combining radiotherapy and immunotherapy is under investigation as a means to improve response rates.
MJ Melake   +16 more
doaj   +1 more source

Home - About - Disclaimer - Privacy